Immunotech Laboratories, Inc. (IMMB) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Immunotech Laboratories, Inc. (IMMB) trades at $0.0002 with AI Score 48/100 (Grade C). Immunotech Laboratories, Inc. focuses on developing and commercializing proprietary proteins for treating immuno-related disorders. The company's flagship compound, ITV-1, targets HIV/AIDS and Hepatitis C. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for IMMB: IMMB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMMB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMMB: 1/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Immunotech Laboratories, Inc. (IMMB) Healthcare & Pipeline Overview
Immunotech Laboratories, Inc. is a pharmaceutical company specializing in the development of proprietary proteins, notably ITV-1, for treating HIV/AIDS, Hepatitis C, and other immuno-related disorders. Operating as a subsidiary of Eco-Petroleum Solutions, Inc., the company focuses on modulating the immune system through its unique therapeutic vaccine.
What Is the Investment Thesis for IMMB?
Immunotech Laboratories, Inc. presents a highly speculative investment opportunity due to its focus on ITV-1, a proprietary protein aimed at treating HIV/AIDS and Hepatitis C. The company's potential hinges on the successful development and commercialization of ITV-1, which could address significant unmet needs in the treatment of these diseases. However, as a subsidiary of Eco-Petroleum Solutions, Inc., its financial performance and strategic direction are closely tied to its parent company. The company's small size and limited resources pose challenges to its ability to navigate the complex regulatory landscape and compete with larger pharmaceutical companies. With a negative P/E ratio of -0.23 and a beta of -77.02, the stock demonstrates high volatility and speculative interest. Investors should carefully consider the risks associated with investing in a small, OTC-traded pharmaceutical company with a limited product pipeline.
Based on FMP financials and quantitative analysis
IMMB Key Highlights
Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc. since June 14, 2017.
- The company's primary product is ITV-1, an immune therapeutic vaccine targeting HIV/AIDS and Hepatitis C.
- The company has a negative Price/Earnings ratio of -0.23, indicating it is not currently profitable.
- The company has a beta of -77.02, suggesting an inverse correlation to market movements and high volatility.
- Immunotech Laboratories, Inc. does not offer a dividend, reflecting its focus on reinvesting earnings into research and development.
Who Are IMMB's Competitors?
IMMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HEWA HealthWarehouse.com, Inc. | $0.11 | +0.00% | $6.29M | 55 |
| YI 111, Inc. | $3.44 | -1.99% | $30.1M | 44 |
| MYCOF Noveris Health Sciences Inc. | $0.73 | +0.00% | $42.7M | 48 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| HITI High Tide Inc. | $2.42 | -1.42% | $213M | 47 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
| CGEM Cullinan Therapeutics, Inc. | $22.52 | +8.06% | $1.38B | 57 |
| DMRA Galecto, Inc. | $30.31 | -6.57% | $1.87B | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMMB's Key Strengths?
Proprietary protein technology (ITV-1).
- Focus on a specific niche within the pharmaceutical industry (immuno-related disorders).
- Potential for patent protection on ITV-1.
- Operates as a subsidiary of Eco-Petroleum Solutions, Inc.
What Are IMMB's Weaknesses?
Small size and limited resources.
- Dependence on a single product (ITV-1).
- Limited market presence.
- OTC market listing.
What Could Drive IMMB Stock Higher?
Clinical trial results for ITV-1 in HIV/AIDS and Hepatitis C (timeline: 12-18 months).
- Potential strategic partnerships with larger pharmaceutical companies (timeline: 6-12 months).
- Research and development efforts to expand the applications of ITV-1.
- Efforts to secure patent protection for ITV-1.
What Are the Key Risks for IMMB?
Financial-distress signal — its Altman Z-Score of -1.14 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-9.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for ITV-1.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in obtaining approvals for ITV-1.
- Limited financial resources and dependence on external funding.
- OTC market listing and associated liquidity risks.
What Are the Growth Opportunities for IMMB?
- Expansion of ITV-1 Applications: Immunotech could explore expanding the applications of ITV-1 beyond HIV/AIDS and Hepatitis C to other immuno-related disorders. The market for immunomodulatory therapies is growing, driven by increasing understanding of immune system dysfunction in various diseases. Successful expansion could significantly increase the market opportunity for ITV-1, although it would require additional research and clinical trials. The timeline for this expansion is estimated at 3-5 years, contingent on regulatory approvals and clinical trial outcomes.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could provide Immunotech with access to additional resources, expertise, and distribution channels. Collaborations could accelerate the development and commercialization of ITV-1 and expand its market reach. The timeline for establishing such partnerships is estimated at 1-2 years, depending on the attractiveness of ITV-1 to potential partners. This could provide a significant boost to Immunotech's growth prospects.
- Geographic Expansion: Expanding its geographic presence beyond the United States could open up new markets for ITV-1. HIV/AIDS and Hepatitis C are global health challenges, and there is significant demand for effective treatments in developing countries. Geographic expansion would require navigating different regulatory environments and establishing distribution networks. The timeline for this expansion is estimated at 2-4 years, depending on the specific target markets and regulatory requirements.
- Development of New Proprietary Proteins: Investing in the development of new proprietary proteins could diversify Immunotech's product pipeline and reduce its reliance on ITV-1. This would require significant investment in research and development, but it could create new revenue streams and enhance the company's long-term growth prospects. The timeline for developing new proprietary proteins is estimated at 3-5 years, depending on the complexity of the research and development process.
- Acquisition by a Larger Pharmaceutical Company: Immunotech could be an attractive acquisition target for a larger pharmaceutical company seeking to expand its portfolio of immunomodulatory therapies. An acquisition would provide Immunotech with access to greater resources and expertise, and it could accelerate the development and commercialization of ITV-1. The timeline for a potential acquisition is uncertain, but it could occur within the next 1-3 years, depending on market conditions and the strategic priorities of potential acquirers.
What Threats Does IMMB Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and clinical trial risks.
- Patent expiration and generic competition.
- Changes in healthcare policies and reimbursement rates.
What Are IMMB's Competitive Advantages?
- Proprietary protein technology (ITV-1).
- Focus on a specific niche within the pharmaceutical industry (immuno-related disorders).
- Potential for patent protection on ITV-1.
What Does IMMB Do?
Immunotech Laboratories, Inc. was founded to develop and commercialize proprietary proteins aimed at treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. The company's primary focus is on its flagship compound, ITV-1 (immune therapeutic vaccine), which is a suspension of irreversible pepsin fraction designed to treat HIV/AIDS and Hepatitis C, as well as to modulate the immune system. ITV-1 represents the core of Immunotech's efforts to provide innovative solutions in the field of immune-related therapies. Headquartered in Monrovia, California, Immunotech operates as a subsidiary of Eco-Petroleum Solutions, Inc., since June 14, 2017. This acquisition has allowed Immunotech to continue its research and development activities under the umbrella of a larger entity. The company's strategy revolves around leveraging its proprietary protein technology to address significant unmet needs in the treatment of viral and immune-related diseases. Immunotech's small team is focused on advancing ITV-1 through various stages of development and exploring its potential applications in other immuno-related conditions. The company aims to establish itself as a key player in the development of novel immunomodulatory therapies.
What Products and Services Does IMMB Offer?
- Develop proprietary proteins for treating immuno-related disorders.
- Focus on the development of ITV-1 (immune therapeutic vaccine).
- Target HIV/AIDS and Hepatitis C with ITV-1.
- Modulate the immune system through their therapeutic vaccine.
- Conduct research and development activities to advance ITV-1.
- Operate as a subsidiary of Eco-Petroleum Solutions, Inc.
How Does IMMB Make Money?
- Develop and commercialize proprietary proteins.
- Generate revenue through the sale of ITV-1.
- Focus on treating HIV/AIDS and Hepatitis C.
- Operate as a subsidiary of Eco-Petroleum Solutions, Inc.
What Industry Does IMMB Operate In?
Immunotech Laboratories, Inc. operates within the medical pharmaceutical industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for HIV/AIDS and Hepatitis C treatments is well-established but continues to evolve with the development of new therapies. Immunotech's focus on proprietary proteins and immune modulation places it in a niche segment of the market, competing with larger pharmaceutical companies that have broader product portfolios and greater resources. The company's success depends on its ability to differentiate ITV-1 and demonstrate its clinical efficacy and safety.
Who Are IMMB's Key Customers?
- Patients with HIV/AIDS.
- Patients with Hepatitis C.
- Healthcare providers treating immuno-related disorders.
Financial Health
Immunotech Laboratories, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.14 places it in the distress zone, a signal of elevated financial risk.
IMMB Valuation & Market Position
Relative to its peer group, IMMB's quantitative score of 48/100 is roughly in line with the peer average of 49/100.
Key Financial Metrics
Return on equity for Immunotech Laboratories, Inc. stands at -9.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -27.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Immunotech Laboratories, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Monrovia, US. The company is led by CEO Jennifer L. Bath. IMMB has traded publicly since 2001.
IMMB Financials
Bull Case vs Bear Case
Bull Case
- Proprietary protein technology (ITV-1).
- Focus on a specific niche within the pharmaceutical industry (immuno-related disorders).
- Potential for patent protection on ITV-1.
- Operates as a subsidiary of Eco-Petroleum Solutions, Inc.
Bear Case
- Small size and limited resources.
- Dependence on a single product (ITV-1).
- Limited market presence.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
IMMB Latest News
No recent news available for IMMB.
IMMB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMMB.
Price Targets
Wall Street price target analysis for IMMB.
IMMB MoonshotScore
What does this score mean?
The MoonshotScore rates IMMB 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Harry H. Zhabilov Jr. McS
CEO
Harry H. Zhabilov Jr. McS serves as the CEO of Immunotech Laboratories, Inc. His background includes experience in managing small teams and overseeing the development of pharmaceutical products. He has a McS degree. His leadership is focused on advancing the company's flagship compound, ITV-1, through the necessary regulatory and clinical milestones. Zhabilov's expertise is crucial in navigating the complex landscape of the pharmaceutical industry and driving the company's strategic initiatives.
Track Record: Under Harry H. Zhabilov Jr.'s leadership, Immunotech Laboratories, Inc. has continued to focus on the development of ITV-1. His tenure has involved navigating the challenges of a small pharmaceutical company operating in a competitive market. Key decisions have included prioritizing research and development efforts and seeking strategic partnerships to support the company's growth. He manages a team of 4 employees.
IMMB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immunotech Laboratories, Inc. may not meet the minimum financial standards or reporting requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may be subject to limited regulatory oversight and may not provide as much information to investors as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility.
- OTC Tier: OTC Other
- Limited liquidity due to OTC trading.
- Lack of regulatory oversight compared to major exchanges.
- Potential for higher price volatility.
- Uncertainty regarding financial reporting and disclosure.
- Dependence on a single product (ITV-1).
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their experience.
- Evaluate the potential market for ITV-1.
- Understand the regulatory landscape and clinical trial risks.
- Review the company's patent protection and intellectual property.
- Monitor the company's news and press releases for updates.
- Consult with a financial advisor before investing.
- Focus on developing treatments for HIV/AIDS and Hepatitis C.
- Existence of a proprietary protein technology (ITV-1).
- Operation as a subsidiary of Eco-Petroleum Solutions, Inc.
- CEO with experience in managing pharmaceutical products.
Immunotech Laboratories, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for IMMB?
IMMB holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Immunotech Laboratories, Inc. focuses on developing and commercializing proprietary proteins for treating immuno-related disorders. The company's flagship compound, ITV-1, targets HIV/AIDS …
What does Immunotech Laboratories, Inc. do?
Immunotech Laboratories, Inc. is a pharmaceutical company focused on developing and commercializing proprietary proteins for treating immuno-related disorders. Its primary product is ITV-1, an immune therapeutic vaccine targeting HIV/AIDS and Hepatitis C. The company operates as a subsidiary of Eco-Petroleum Solutions, Inc. and aims to modulate the immune system through its unique therapeutic vaccine.
What do analysts say about IMMB stock?
As a thinly traded OTC stock with limited analyst coverage, there is no readily available consensus view on IMMB. The company's valuation is difficult to assess due to its lack of profitability and limited financial disclosures.
What are the main risks for IMMB?
The main risks for Immunotech Laboratories, Inc. include clinical trial failures or delays for ITV-1, competition from larger pharmaceutical companies with greater resources, regulatory hurdles and delays in obtaining approvals for ITV-1, limited financial resources and dependence on external funding, and the OTC market listing and associated liquidity risks.
What are the key factors to evaluate for IMMB?
Immunotech Laboratories, Inc. (IMMB) holds an AI score of 48/100 (low). presents a highly speculative investment opportunity due to its focus on ITV-1, a proprietary protein aimed at treating HIV/AIDS and Hepatitis C. Not financial advice.
How frequently does IMMB data refresh on this page?
IMMB's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IMMB's recent stock price performance?
Immunotech Laboratories, Inc. (IMMB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary protein technology (ITV-1). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMMB overvalued or undervalued right now?
Immunotech Laboratories, Inc. (IMMB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IMMB before investing?
Before investing in Immunotech Laboratories, Inc. (IMMB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited publicly available data.
- OTC market stocks carry higher risk than exchange-listed stocks.
- Financial data may not be fully up-to-date.